Evidence map›Paper›PMID 42412801›Full record

ArticleBioinformatics (Oxford, England)2026

Bridging the phenotype-target gap for molecular generation via multi-objective reinforcement learning.

Haotian Guo, Hui Liu

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Haotian GuoCollege of Computer and Information Engineering, Nanjing Tech University, Nanjing, Jiangsu 211800, China.
Hui LiuCollege of Computer and Information Engineering, Nanjing Tech University, Nanjing, Jiangsu 211800, China.ORCID 0000-0001-7158-913X

Funding

National Natural Science Foundation of China 62372229Natural Science Foundation of Jiangsu Province BK20231271
6 · The paper itself

Abstract

motivationThe generation of high-quality candidate molecules remains a central challenge in AI-driven drug design. Current phenotype-based and target-based strategies each suffer limitations, either incurring high experimental costs or overlooking system-level cellular responses. To bridge this gap, we propose XMolRL, a novel generative framework that synergistically integrates phenotypic and target-specific cues for de novo molecular generation.

resultsThe phenotype-guided generator is first pretrained on expansive drug-induced transcriptional profiles and subsequently fine-tuned via multi-objective reinforcement learning (RL). Crucially, the reward function fuses docking affinity and drug-likeness scores, augmented with ranking loss, prior-likelihood regularization, and entropy maximization. The multi-objective RL steers the model toward chemotypes that are simultaneously potent, diverse, and aligned with the specified phenotypic effects. Extensive experiments demonstrate XMolRL's superior performance over state-of-the-art phenotype-based and target-based models across multiple well-characterized targets. Our generated molecules exhibit favorable drug-like properties, high target affinity, and inhibitory potency (IC50) against cancer cells. This unified framework showcases the synergistic potential of combining phenotype-guided and target-aware strategies, offering a more effective solution for de novo drug discovery. AVAILABILITY AND IMPLEMENTATION: The source code and datasets are available at: https://github.com/hliulab/XMolRL. The archived version of the source code and test data can be found at: https://doi.org/10.5281/zenodo.19607680.

Indexed as

Computational BiologyDrug DesignDrug DiscoveryAlgorithmsGenerative Artificial IntelligenceHumansPhenotypeReinforcement Machine Learning

Identifiers

PMID42412801
PMCPMC13340265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.